Founding Partner at i&i Bio
Check size: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Ivan Vohlmuth invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Present the science, validation, IP, development and regulatory path, team, milestone budget and why i&i Bio's regional network matters.
Validated science, protectable intellectual property, credible translational plans and founders who can move discoveries toward clinical or commercial milestones.
No formal pass list is public. Projects without strong scientific validation, life-science relevance or a feasible development path appear less aligned.